

| Indices | Value | Pts | Chg (%) |
|---------------------|----------|---------|---------|
| SENSEX | 34101.13 | 160.69 | 0.47 |
| NIFTY | 10458.65 | 41.50 | 0.40 |
| SGX NIFTY* | 10494.50 | 26.50 | 0.25 |
| DOW Jones | 24483.05 | 293.60 | 1.21 |
| S&P 500 | 2663.99 | 21.80 | 0.83 |
| Nasdaq | 7140.25 | 71.22 | 1.01 |
| FTSE | 7258.34 | 1.20 | 0.02 |
| CAC | 5309.22 | 31.28 | 0.59 |
| DAX | 12415.01 | 121.04 | 0.98 |
| Shanghai Composite* | 3167.89 | (12.27) | (0.39) |
| Nikkei* | 21789.00 | 128.72 | 0.59 |
| Hang Seng* | 30798.00 | (33.28) | (0.11) |

*As at 8.30 am

| Most Active Call & Put Symbol | Strike Price | OI | Chg (%) |
|-------------------------------|--------------|---------|---------|
| NIFTY | 10500 CE | 4101000 | (6.45) |
| NIFTY | 10400 PE | 4495350 | 42.60 |

| Commodity | Value | Pts | Chg (%) |
|-------------------|-------|----------|---------|
| NYMEX Crude (USD) | 66.85 | (0.22) | (0.33) |
| Brent Crude (USD) | 71.78 | (0.24) | (0.33) |
| Gold (INR) | 31002 | (353.00) | (1.13) |
| Silver (INR) | 38668 | (513.00) | (1.31) |
| Copper (INR) | 442 | (6.35) | (1.42) |
| Zinc (INR) | 202 | (8.40) | (3.99) |
| Cotton (INR) | 20780 | 10.00 | 0.05 |

| Currency | Value | Pts | Chg (%) |
|--------------|-------|--------|---------|
| USD/Rupee | 64.97 | (0.05) | (0.07) |
| Euro/Rupee | 80.30 | 0.25 | 0.31 |
| Pound/Rupee | 92.19 | 0.29 | 0.32 |
| Euro /USD | 1.23 | 0.00 | 0.02 |
| Dollar Index | 89.77 | 0.02 | 0.02 |

| Volatility | Value | Pts | Chg (%) |
|------------|-------|--------|---------|
| CBOE VIX | 18.49 | (1.75) | (8.65) |
| India VIX | 14.56 | 0.06 | 0.41 |

| Interest Rates | Value | Bps change |
|-------------------|-------|------------|
| India 10-Yr Yield | 7.49% | 3 |
| US 10-Yr Yield | 2.82% | 4 |

| Trade Statistics | BSE | NSE | F & O |
|--------------------|------------|------------|------------|
| Turnover (INR Crs) | 3538.74 | 29398.17 | 1358258.17 |
| Advance (Nos) | 1116 (40%) | 733 (40%) | NA |
| Declines (Nos) | 1563 (55%) | 1040 (55%) | NA |
| Unchanged | 138 (5%) | 90 (5%) | NA |

Market Summary

The market ended on a positive note on Thursday. The Market breadth was negative with 3 gainers for every 4 losers on BSE. 1116 shares advanced whereas 1563 shares declined and 138 shares were unchanged on BSE.

BSE Sensex gained 161 points or (0.5%) to close at 34101. Nifty 50 was up 42 points or (0.4%) to settle at 10459. BSE Mid-Cap index lost 21 points or (0.1%) to settle at 16601. BSE Small-Cap index declined 49 points or (0.3%) to settle at 17935.

Top gainer in BSE Sensex were TCS (4.0%), Infosys (3.4%), Axis Bank (1.6%), ICICI Bank (0.8%) and Tata Motors (D) (0.8%) whereas top loser in BSE were Dr Reddys Labs (2.0%), Tata Steel (1.5%), SBI (1.2%), Sun Pharma (1.1%) and Adani Ports (1.1%).

US markets closed positive, Dow Jones Industrial Average closed at 24483, advancing 294 points (1.2%), S&P 500 was up 22 points (0.8%) to close at 2664 and Nasdaq advanced 71 points (1.0%) to close at 7140.

European markets closed positive, FTSE advanced 1 points (0.0%) to close at 7258, CAC was up 31 points (0.6%) to close at 5309 and DAX gained 121 points (1.0%) to close at 12415.

Macro News

- The government has invited bids from merchant bankers for managing the listing process of two PSUs NEEPCO and MSTC. The government currently holds 89.85 per cent stake in trading firm MSTC and the balance 10.15 per cent is held by the members of the Steel Furnace Association of India and Ispat Industries Ltd. North Eastern Electric Power Corporation Ltd (NEEPCO, which meets about 35 per cent of the energy requirement of the North-East region, is wholly-owned by the government. The listing would entail disinvestment of a portion of paid-up equity of NEEPCO and MSTC through a prospectus based Initial Public Offer (IPO) in the domestic market, the Department of Investment and Public Asset Management (DIPAM) said while inviting bids from merchant bankers.

- Giving major relief to budding entrepreneurs, the government on Thursday allowed startups to avail tax concession only if total investment including funding from angel investors does not exceed INR 100 million. As per a notification by the commerce and industry ministry, an angel investor picking up stakes in a startup should have a minimum net worth of INR 20 million or should have an average returned income of over INR 2.5 million in the preceding three financial years.

| Institutional ActivityCash | 12-Apr | Apr'2018 |
|----------------------------|--------------|---------------|
| FII (INRCrs) | | |
| Buy | 4714 | 36062 |
| Sell | 4345 | 39015 |
| Net | 369 | (2954) |
| DII (INRCrs) | | |
| Buy | 3263 | 28294 |
| Sell | 3878 | 24972 |
| Net | (616) | 3322 |

| FII Derivative Statistics (NSE) | | | | |
|---------------------------------|------------------|------------------|----------|---------|
| Particulars | Buy (INR Crs) | Sell (INR Crs) | OI (Nos) | Chg (%) |
| INDEX FUTURES | 2135.10 | 1819.84 | 196906 | (1.82) |
| INDEX OPTIONS | 104444.72 | 103678.93 | 834795 | 3.44 |
| STOCK FUTURES | 8620.26 | 8375.23 | 1115127 | 0.76 |
| STOCK OPTIONS | 5954.32 | 5965.21 | 88376 | 7.43 |
| Total | 121154.39 | 119839.21 | | |

| Gainers & Losers | | Price | Chg (%) |
|----------------------|---------|-------|---------|
| Gainers (INR) | | | |
| TCS | 3137.30 | | 4.04 |
| Infosys | 1162.25 | | 3.41 |
| Axis Bank | 548.30 | | 1.63 |
| ICICI Bank | 286.45 | | 0.83 |
| Tata Motors (D) | 202.15 | | 0.80 |
| Losers (INR) | | | |
| Dr Reddys Labs | 2058.80 | | (1.97) |
| Tata Steel | 598.55 | | (1.51) |
| SBI | 254.30 | | (1.17) |
| Sun Pharma | 514.85 | | (1.12) |
| Adani Ports | 373.50 | | (1.11) |

| Sectoral Performance | Value | Pts | Chg (%) |
|-----------------------|----------|----------|---------|
| S&P BSE Small Cap | 17934.83 | (48.63) | (0.27) |
| S&P BSE Mid-Cap | 16600.67 | (20.91) | (0.13) |
| S&P BSE Auto | 25440.13 | (2.39) | (0.01) |
| S&P BSE BANKEX | 28272.65 | 99.39 | 0.35 |
| S&P BSE Capital Goods | 19198.69 | 35.50 | 0.19 |
| S&P BSE FMCG | 10663.18 | (16.83) | (0.16) |
| S&P BSE Healthcare | 13603.54 | (99.40) | (0.73) |
| S&P BSE IT | 12717.40 | 391.52 | 3.18 |
| S&P BSE Metals | 13956.37 | (199.19) | (1.41) |
| S&P Oil & Gas | 14703.74 | (12.13) | (0.08) |

Key News

Dosti-Suraksha JV to acquire Jaypee Infra for INR 7,350 crore

Lakshadweep Pvt Ltd., a joint venture formed by two companies promoted by people with ties to billionaire Dilip Shanghvi, is set to acquire Jaypee Infratech, the insolvency-hit developer that has to deliver about 25,000 apartments in Noida and is the operator of the Taj Expressway. The proposed transaction by Lakshadweep, a JV between Suraksha Asset Reconstruction Company and Mumbai-based Dosti Reality, will result in the eventual delisting of Jaypee Infratech as almost all its equity capital will be written off, said two people familiar with the development. The JV has outdone other leading contenders by a huge margin with a INR 7,350 crore bid.

NBCC secures total business worth INR 769.96 crore in March

NBCC (India) has secured the total business of around INR 769.96 crore in the month of March, 2018. The company had secured total Business of around INR 242 crore in the month of February, 2018.

ITI's total order book stands at INR 3671 crore in FY18

ITI's total order book stood at INR 3671 crore in Fiscal Year 2017-18. Besides, the company's total turnover for the period ended March 31, 2018 stood at INR 1701 crore as compared to INR 1621 crore for the previous year ended March 31, 2017. The company has made a net profit of INR 27 crore without grants after a long gap of 16 years.

Capacite Infraprojects bags contract worth of INR 162.67 crore

Capacite Infraprojects has received contract worth INR 162.67 crore (excluding taxes), from Sea View Developers, a Brookfield Investee Company for Civil and Structure work package for construction of Tower 11 and Multi Level Car park.

Aster DM Healthcare enters into agreement with SCDC

Aster DM Healthcare has entered into an agreement with Subramanya Constructions & Development Company (SCDC), a leading real estate developer, to construct a new hospital in Chennai. This 500 bedded, state of the art, multi-specialty hospital is expected to be commissioned in 2020. The hospital, which would be situated at a prime location in Chennai, will provide advanced healthcare services to the residents of Tamil Nadu and customers from other states in India as well as overseas. Aster DM Healthcare, which was recently listed at NSE and BSE already operates 11 hospitals in South India with 4037 installed beds. The new facility is in line with Aster DM's strategy of strengthening its presence in India.

International Data

| Country | Data | Forecast | Previous |
|---------|-----------------------|----------|----------|
| UK | BOE Gov Carney Speaks | NA | NA |

SharadAvasthi

Head - Equity Research

sharad.avasthi@spagroupindia.com

Tel.: +91-022-42895600

Ext.206

Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking company having membership of NSE, BSE & MCX for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasecurities.com.

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

General Disclosures: This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economicstimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

| Disclosure of interest statement | Yes/No |
|---|--------|
| SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company | No |
| SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month immediately preceding the date of the publication of the research report or date of public appearance. | No |
| Investment banking relationship with the company covered | No |
| Any other material conflict of interest at the time of publishing the research report | No |
| Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months: | |
| • Managing/co-managing public offering of securities | |
| • Investment banking/merchant banking/brokerage services | No |
| • products or services other than those above | |
| • in connection with research report | |
| Whether Research Analyst has served as an officer, director or employee of the subject company covered | No |
| Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company; | No |

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

For More Information Visit Us At : www.spasecurities.com

SPA CAPITAL SERVICES LIMITED

Investment Advisory services,
AMFI Reg. No. ARN-007

SPA Capital Advisors Limited

SEBI registered Category-1
Merchant Bankers
SEBI Regn. No. INM000010825

SPA COMTRADE PRIVATE LIMITED

SPA INSURANCE BROKING SERVICES LTD.

Direct Broker for Life and General
Insurance Broking
IRDA Lic. Code No. DB053/03

SPA Securities Ltd

NSE Cash
NSE Future & Option
NSE Currency Derivatives
BSE Cash
BSE Currency Derivatives
MCX-SX Cash
MCX-SX Future & Option
MCX-SX Currency Derivatives
Mutual Fund
CDSL DP
NSDL DP
SEBI Research Analyst

SEBI Reg. Nos.

INB231178238
INF231173238
INE231178238
INB011178234
INE011178234
INB261178231
INF261178231
INE261178238
ARN 77388
IN-DP-CDSL-485-2008
IN-DP-NSDL-316-2009
INH100002615